RxPONDER: Chemoendocrine Therapy vs Endocrine Therapy Alone in Hormone-Receptor–Positive, HER2-Negative, Node-Positive Breast Cancer with Recurrence Score ≤25

Primary endpoint (IDFS, overall population): 92.2% vs 91.0% at 5 years — HR 0.86 (95% CI 0.72–1.03; P=0.10) IDFS — premenopausal women: 93.9% vs 89.0% at 5 years — HR 0.60 (95% CI 0.43–0.83; P=0.002) IDFS — postmenopausal women: 91.3% vs 91.9% at 5 years — HR 1.02 (95% CI 0.82–1.26; P=0.89) Safety signal: No safety data reported in this publication

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

RxPONDER addressed a critical question in early breast cancer: does adding chemotherapy to endocrine therapy improve outcomes for women with hormone-receptor–positive, HER2-negative, node-positive breast cancer and a low-to-intermediate Oncotype DX recurrence score? In the overall population, the addition of chemotherapy did not produce a statistically significant improvement in invasive disease–free survival. However, a striking and statistically significant interaction with menopausal status fundamentally changed how this trial's results translate to practice.

For premenopausal women, chemotherapy provided a clear and clinically meaningful benefit — reducing the risk of invasive disease recurrence, new primary cancer, or death by approximately forty percent. This benefit was consistent across recurrence score categories, tumor sizes, nodal burden, and tumor grades. For postmenopausal women, there was no chemotherapy benefit whatsoever, regardless of recurrence score. This menopausal status–driven distinction has reshaped adjuvant treatment decisions for node-positive, HR-positive breast cancer, establishing that the recurrence score alone is insufficient to guide chemotherapy decisions in premenopausal women with one to three positive nodes.

Clinicians should recognize that the chemotherapy benefit in premenopausal women may be partly mediated by chemotherapy-induced ovarian suppression rather than a direct cytotoxic effect — a hypothesis supported by the low rate of prescribed ovarian suppression in the endocrine-only arm and the observation that the benefit was most pronounced in younger premenopausal women. This raises the question of whether ovarian suppression alone could substitute for chemotherapy in some of these patients.

Trial Overview

Study Design

• Trial name and registration: RxPONDER (A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer), NCT01272037
• Design: Phase 3, randomized, open-label, controlled trial. This publication reports the prespecified third interim analysis.
• Randomization: 1:1 (chemoendocrine therapy : endocrine therapy alone), stratified by recurrence score (0–13 or 14–25), menopausal status (premenopausal or postmenopausal), and type of axillary surgery (sentinel-node biopsy or axillary lymph-node dissection).
• Setting: Adjuvant treatment of hormone-receptor–positive, HER2-negative breast cancer with one to three positive axillary lymph nodes and Oncotype DX 21-gene recurrence score ≤25.
• Enrollment period: February 2011 to September 2017.

Patient Population

• Key eligibility: Women ≥18 years of age; histologically or cytologically confirmed HR-positive, HER2-negative, noninflammatory breast cancer; one to three positive axillary lymph nodes (N1); undergone primary surgery with sentinel-node biopsy or axillary lymph-node dissection; eligible for a chemotherapy regimen containing a taxane, an anthracycline, or both; Oncotype DX 21-gene recurrence score of 0 to 25; no distant metastasis.
• Biomarker selection: Oncotype DX 21-gene recurrence score 0–25.
• Sample size flow: 9,383 women registered for screening → 5,083 randomized → 5,018 eligible and participated → 4,984 included in the ITT analysis (2,487 chemoendocrine; 2,497 endocrine-only). 65 participants were deemed ineligible after randomization; 34 withdrew consent.

Baseline Characteristics

Treatment Protocol

Experimental Arm: Chemoendocrine (n=2,547 randomized; n=2,487 analyzed)

Chemotherapy followed by endocrine therapy. The preferred chemotherapy regimen for premenopausal women was an anthracycline and a taxane (in 54%); the preferred regimen for postmenopausal women was a taxane plus cyclophosphamide (in 57%).

• Dose and schedule: Not reported in this publication.
• Treatment duration: Not reported in this publication.
• Median treatment duration: Not reported in this publication.
• Median relative dose intensity: Not reported in this publication.

Of note, 402 participants (16.2%) assigned to chemoendocrine therapy declined the assigned treatment. Among postmenopausal women, 300 of 1,658 (18.1%) declined chemoendocrine therapy. Among premenopausal women, 102 of 829 (12.3%) declined chemoendocrine therapy. These participants were included in the ITT analysis in their assigned group.

Control Arm: Endocrine-Only (n=2,536 randomized; n=2,497 analyzed)

Endocrine therapy alone.

• Dose and schedule: Not reported in this publication.
• Treatment duration: Not reported in this publication.
• Median treatment duration: Not reported in this publication.

144 participants (5.8%) assigned to endocrine-only therapy declined the assigned treatment. Among postmenopausal women, 79 of 1,671 (4.7%) declined. Among premenopausal women, 65 of 826 (7.9%) declined.

Regarding ovarian function suppression: 12.7% of all premenopausal women had suppression of ovarian function within 12 months of randomization — 6.3% in the chemoendocrine group and 19.0% in the endocrine-only group. Among premenopausal women ≤40 years of age in the endocrine-only group, 36.6% had received ovarian suppression.

Efficacy Outcomes

Primary Endpoint: Invasive Disease–Free Survival (IDFS) — Overall Population

Definition: Time from date of randomization to date of a first invasive recurrence (local, regional, or distant), a new invasive primary cancer (breast cancer or another type of cancer), or death from any cause. Analysis population: Intention-to-treat population of eligible participants (N=4,984). Statistical method: Cox regression model adjusted for continuous recurrence score and menopausal status; log-rank test. Median follow-up: 5.3 years Information fraction: 58% of the total expected 832 events (481 events observed).

The primary analysis tested whether the relative chemotherapy benefit (treatment-by-recurrence score interaction) increased with higher recurrence score. This interaction was not significant (P=0.35). The recurrence score was prognostic: HR per unit change in recurrence score 1.05 (95% CI 1.04–1.07; P<0.001).

Overall invasive disease–free survival at 5 years was 91.6%.

Chemoendocrine: 5-year IDFS 92.2% (220 events in 2,487 patients) Endocrine-only: 5-year IDFS 91.0% (261 events in 2,497 patients) Comparison: HR 0.86 (95% CI 0.72–1.03; P=0.10)

The primary endpoint was not met in the overall population.

Critical Finding: Treatment-by-Menopausal Status Interaction

A prespecified test for interaction between treatment assignment and menopausal status was significant (P=0.008), leading to separate prespecified analyses:

IDFS — Postmenopausal Women

Analysis population: Postmenopausal women in the ITT population (chemoendocrine n=1,658; endocrine-only n=1,671). Statistical method: Cox regression model adjusted for continuous recurrence score.

Chemoendocrine: 5-year IDFS 91.3% (163 events) Endocrine-only: 5-year IDFS 91.9% (169 events) Comparison: HR 1.02 (95% CI 0.82–1.26; P=0.89)

There was no chemotherapy benefit in postmenopausal women. This finding was confirmed in the per-protocol analysis: HR 0.97 (95% CI 0.77–1.22; P=0.81).

The interaction between treatment and recurrence score categories (0–13 vs 14–25) was not significant (P=0.89) in postmenopausal women — chemotherapy showed no benefit regardless of recurrence score.

In 90 of the 332 events (27.1%) among postmenopausal women, distant recurrences were the first event.

IDFS — Premenopausal Women

Analysis population: Premenopausal women in the ITT population (chemoendocrine n=829; endocrine-only n=826). Statistical method: Cox regression model adjusted for continuous recurrence score.

Chemoendocrine: 5-year IDFS 93.9% (57 events) Endocrine-only: 5-year IDFS 89.0% (92 events) Absolute difference: 4.9 percentage points Comparison: HR 0.60 (95% CI 0.43–0.83; P=0.002)

This was confirmed in the per-protocol analysis: HR 0.53 (95% CI 0.37–0.75; P<0.001).

In 76 of the 149 events (51.0%) among premenopausal women, distant recurrences were the first event.

Key Secondary Endpoints

Distant Relapse–Free Survival (DRFS) — All Participants

Definition: Time to distant recurrence or death from any cause. Analysis population: ITT population of eligible participants. Whether formally tested in the statistical hierarchy was not reported in this publication. The publication cautions that "caution should be used in interpretation of the results of the secondary analyses."

Chemoendocrine: 5-year DRFS 94.9% (150 events) Endocrine-only: 5-year DRFS 93.9% (175 events) Comparison: HR 0.88 (95% CI 0.71–1.09; P=0.25)

DRFS — Postmenopausal Women

Chemoendocrine: 5-year DRFS 94.4% (112 events) Endocrine-only: 5-year DRFS 94.4% (112 events) Absolute difference at 5 years: 0.1 percentage point (95% CI −0.8 to 1.7) Comparison: HR 1.05 (95% CI 0.81–1.37; P=0.70)

DRFS — Premenopausal Women

Chemoendocrine: 5-year DRFS 96.1% (38 events) Endocrine-only: 5-year DRFS 92.8% (63 events) Absolute difference at 5 years: 3.3 percentage points (95% CI 0.8–5.8) Comparison: HR 0.58 (95% CI 0.39–0.87; P=0.009)

Safety

No safety data are reported in this publication. The paper focuses entirely on efficacy endpoints. Standard safety metrics (any-grade AE, grade ≥3 AE, serious AE, treatment-related AE, discontinuation due to AE, dose reduction, treatment-related deaths) were not reported. Safety data may be available in the supplementary appendix, which was not included in this extraction.

Subgroup Analyses

The trial reported subgroup forest plots separately for postmenopausal women (Figure 3A) and premenopausal women (Figure 3B). Interaction p-values were reported for selected subgroups. These subgroup analyses were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Postmenopausal Women — IDFS Subgroups

The interaction between treatment and recurrence score categories in postmenopausal women was not significant (P=0.89). No subgroup of postmenopausal women showed a chemotherapy benefit.

Premenopausal Women — IDFS Subgroups

The chemotherapy benefit in premenopausal women was broadly consistent across subgroups. The benefit appeared most pronounced in women younger than 50 years: HR 0.48 (95% CI 0.32–0.72) for age <50 years vs HR 0.98 for age ≥50 years, although the interaction between age and treatment was not significant (P=0.06).

Notably, in premenopausal women, the chemotherapy benefit was observed regardless of recurrence score — both in the 0–13 range (HR 0.49; 95% CI 0.24–0.99) and the 14–25 range (HR 0.63; 95% CI 0.43–0.91).

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

TAILORx addressed a parallel question in node-negative disease and established that women with RS 11–25, node-negative, HR-positive breast cancer do not benefit from chemotherapy — with the important exception of a possible benefit in younger women, consistent with the RxPONDER findings. RxPONDER extends this framework to node-positive disease but arrives at a fundamentally different conclusion by menopausal status: in node-positive premenopausal women, chemotherapy is beneficial even at low recurrence scores, whereas in postmenopausal women, it provides no benefit up to a score of 25.

The monarchE trial tested adjuvant abemaciclib (a CDK4/6 inhibitor) plus endocrine therapy in higher-risk, node-positive, HR-positive breast cancer. While the populations overlap, monarchE selected for higher clinical risk and included patients with RS >25. For postmenopausal women with RS ≤25 and 1–3 positive nodes — those for whom RxPONDER shows no chemotherapy benefit — the appropriate adjuvant intensification strategy remains a topic of active investigation.

Grey Zones and Unanswered Questions

• Is the premenopausal chemotherapy benefit driven by ovarian suppression? Only 6.3% of premenopausal women in the chemoendocrine group and 19.0% in the endocrine-only group received prescribed ovarian function suppression within 12 months. Chemotherapy commonly induces ovarian suppression, which could account for some or all of the observed benefit. Whether ovarian function suppression with a GnRH agonist could replace chemotherapy in this population is a critical unanswered question.

• Premenopausal women aged ≥50 years saw no benefit (HR 0.98). This subgroup analysis (P for interaction=0.06) suggests the benefit may be confined to younger premenopausal women. However, the trial was not powered for this comparison, and the interaction was not statistically significant. Clinicians face genuine uncertainty about chemotherapy's value for older premenopausal patients with low recurrence scores.

• No safety data were reported. The toxicity burden of adjuvant chemotherapy — including neutropenia, neuropathy, cardiotoxicity, secondary malignancies, and fertility impairment — is substantial and well characterized from other trials, but the specific safety experience of this trial population is unknown from this publication.

• Overall survival data are immature. At a median follow-up of 5.3 years and 58% information fraction, OS was described as "not mature." Whether the IDFS benefit in premenopausal women translates to an OS advantage remains unknown and is of paramount importance for a potentially curable population.

• The 16.2% non-adherence rate in the chemoendocrine arm dilutes the ITT estimate of chemotherapy benefit. The per-protocol analysis in premenopausal women (HR 0.53; 95% CI 0.37–0.75; P<0.001) suggests the true benefit of actually receiving chemotherapy may be larger than the ITT estimate.

Clinical Implications

Rationale and Clinical Context

Before RxPONDER, the role of chemotherapy in node-positive, HR-positive, HER2-negative breast cancer with low-to-intermediate Oncotype DX recurrence scores was uncertain. TAILORx had clarified this question for node-negative disease, but node-positive patients were excluded from that trial. RxPONDER was designed to determine whether the recurrence score could predict chemotherapy benefit in the node-positive setting. The finding that menopausal status — not recurrence score — was the critical modifier of chemotherapy benefit fundamentally reshaped the adjuvant treatment algorithm.

Monitoring and Long-Term Follow-Up

With a median follow-up of 5.3 years and an information fraction of only 58%, longer follow-up is essential. Late recurrences are a hallmark of HR-positive breast cancer, and the 5-year IDFS rates — while reassuring — do not capture the full picture. Extended endocrine therapy decisions, monitoring for late distant recurrences, and OS data will be critical for long-term treatment planning.

De-Escalation Considerations

For postmenopausal women with HR-positive, HER2-negative breast cancer, one to three positive nodes, and a recurrence score ≤25, RxPONDER provides strong evidence to omit adjuvant chemotherapy. The HR of 1.02 with no benefit across any subgroup — including RS 14–25, larger tumors, and multiple positive nodes — supports endocrine therapy alone as the standard of care.

For premenopausal women, the data support adjuvant chemotherapy across this recurrence score range. However, the potential role of ovarian function suppression as a substitute for chemotherapy remains an active area of investigation.

Unanswered Questions

The two most practice-relevant open questions are: (1) whether ovarian function suppression (with or without enhanced endocrine therapy) can replace chemotherapy for premenopausal women with low recurrence scores and limited nodal disease; and (2) the long-term overall survival outcomes, particularly whether the IDFS benefit in premenopausal women translates to a survival advantage at 10 years.

Regulatory and Guideline Status

Regulatory

• FDA: The Oncotype DX 21-gene assay is cleared by the FDA as a prognostic and predictive tool for breast cancer. The RxPONDER trial informed the interpretation of recurrence score results in the node-positive setting but did not lead to a separate regulatory action for a therapeutic product. Regulatory status should be verified with current FDA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current status at FDA.gov.

Guidelines

• NCCN: The NCCN Clinical Practice Guidelines for Breast Cancer [3] incorporate RxPONDER results into recommendations for adjuvant systemic therapy in HR-positive, HER2-negative, node-positive disease. For postmenopausal women with 1–3 positive nodes and RS ≤25, endocrine therapy alone is recommended. For premenopausal women with 1–3 positive nodes and RS ≤25, chemoendocrine therapy is recommended. The guidelines note the potential confounding role of ovarian function suppression.

Companion Diagnostics

The Oncotype DX 21-gene recurrence score assay (Exact Sciences) is the companion diagnostic for treatment decision-making in this population. A recurrence score result ≤25 is required to apply the RxPONDER findings.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347. doi:10.1056/NEJMoa2108873
2. Oncotype DX Breast Recurrence Score test. Exact Sciences. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
4. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
5. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998.